Jardiance® (empagliflozin) now approved in India for treatment of chronic kidney disease
Jardiance® (empagliflozin) now approved in India
Search
Women in STEM 2022
Meet three of Boehringer Ingelheim's female scientists and learn why and how women are making a difference in STEM. Click here to find out more.
Biberach
Boehringer Ingelheim has a research and production network across the globe. Click here to read and find out information about our Biberach site.
1885-1948
In 1885, Albert Boehringer purchased a small tartar factory in the Rhine-Hessian village of Nieder-Ingelheim. Click here to learn more about our history.
Boehringer Ingelheim's Board of Managing Directors | Boehringer Ingelheim
Read more about Boehringer Ingelheim's board of managing directors, with information on all five members and their respective responsibilities.
Boehringer Ingelheim receives ad-interim injunctions against four more domestic pharma companies for patent infringement of its anti-diabetes drug
Boehringer Ingelheim receives ad-interim injunctions against four more domestic pharma companies for patent infringement of its anti-diabetes drug.
Quick response in fighting Foot-and-Mouth-Disease
Colleagues from the Veterinary Public Health helped to contain an outbreak of Foot-and-Mouth Disease (FMD) on the island of Rodrigues in just six days.
Obesity osteoarthritis in pets a blind spot
Body weight is just one indicator among many when it comes to a pet’s health status, but there are some diseases associated with it. Learn more here.
Keep water clean
Human beings can’t survive without water. Further, the safe production of medicines depends on clean drinking water. Click here to find out more.
1988-2015
Following the death of Hubertus Liebrecht (1991), the owning family made some fundamental decisions regarding the company’s alignment. Learn more here.
Circular economy towards the future
Boehringer Ingelheim uses eco-design to shape and develop animal health products with an improved environmental profile. Click here to read more.
Watch out: the tick season is there!
From a Southern tick species spreading throughout Europe to the fact American pop singer Justin Bieber is battling Lyme disease, ticks are in the news.
COVID-19 Boehringer Ingelheim Singapore JSS donations
Boehringer Ingelheim Singapore donates government payouts for more good causes, giving back to patients and animals who need it the most. Learn more.
In France, it’s time to be(e)
How about producing honey and contributing to environmental sustainability during your work hours? Click here to read more about this story.
Social Support
People living with cancer share their diagnosis stories and perspectives on the importance of social support. Click here to find out and learn more.
Boehringer Ingelheim expands animal health portfolio in India with the launch of NexGard® (afoxolaner) Small and Medium
Boehringer Ingelheim expands animal health portfolio in India with the launch of NexGard® (afoxolaner) Small and Medium
EMPEROR-Preserved trial reveals that Empagliflozin reduces the risk of hospitalization for heart-failure and cardiovascular death
EMPEROR-Preserved trial reveals that Empagliflozin reduces the risk of hospitalisation for heart-failure and cardiovascular death. Find out more here.
Boehringer Ingelheim launches additional heart failure indication for Jardiance® (empagliflozin) in India
Boehringer Ingelheim launches additional heart failure indication for Jardiance® (empagliflozin) in India. Click here to find out and learn more.
Pet industry trends Millennials
Millennials are now shaping pet markets and facing new issues in pet healthcare. Click here to read and learn more about this new generation of pet owners.
Afrika Kommt! - The Ripple Effect
What the Afrika Kommt! Fellowship Program means to Boehringer Ingelheim
COVID-19 Boehringer Ingelheim Singapore charity donations
Find out how Boehringer Ingelheim Singapore is offering support for healthcare workers and vulnerable communities. Click here to learn more.
CDSCO approves SPEVIGO® (spesolimab) - the first treatment option for generalized pustular psoriasis flares in adults
CDSCO approves SPEVIGO® (spesolimab)